8 completed, 3 active not recruiting, 2 terminated, 1 not yet recruiting. 16 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 8, Active not recruiting 3, Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Indolent Non-hodgkin Lymphoma: new trials by email Literature Review of Indolent Non-hodgkin Lymphoma trials Research Report on Indolent Non-hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Obinutuzumab, Glofitamab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Active not recruiting | Reid Merryman, MD | 47 | 2023-07-18 | 2026-09-25 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma IBI376 - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 81 | 2020-04-07 | 2024-06-05 |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 103 | 2019-09-24 | 2024-09-19 |
| Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Phase 2 | Active not recruiting | David Bond, MD | 30 | 2019-01-02 | 2026-02-06 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years Obinutuzumab, Bendamustine - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Prof. Dr. Wolfgang Hiddemann | 46 | 2017-12-12 | 2023-03-31 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Completed | Kite, A Gilead Company | 159 | 2017-06-06 | 2025-12-23 |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma Ibrutinib, GA 101 - Indolent Non-Hodgkin Lymphoma | Phase 2 | Unknown | Ludwig-Maximilians - University of Munich | 98 | 2016-04-01 | 2021-05-07 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion - Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 35 | 2015-11-13 | 2025-04-24 |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 129 | 2013-06-17 | 2023-09-07 |
| Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia Vismodegib - Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Terminated | The Lymphoma Academic Research Organisation | 31 | 2013-02-01 | 2017-03-13 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 73 | 2008-06-25 | 2019-12-27 |
Lymphoma, Follicular (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Large B-Cell, Diffuse (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Anemia, Aplastic (1) · Anemia, Refractory (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Neoplasms by Histologic Type (12) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Lymphoma (10) · Lymphoma, B-Cell (9) · Lymphoma, Non-Hodgkin (8) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Leukemia (4) · Pathologic Processes (4)
obinutuzumab (5) · Cyclophosphamide (4) · Rituximab (3) · Bendamustine Hydrochloride (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · duvelisib (2) · fludarabine (2) · fludarabine phosphate (2) · ibrutinib (2) · 13-valent pneumococcal vaccine (1) · CT-P10 (1) · Cord Blood Stem Cell Transplantation (1) · Cryosurgery (1) · Cyclosporine (1)
SecuraBio (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Antengene Corporation (1) · David Bond, MD (1) · Emory University (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Kite, A Gilead Company (1) · Ludwig-Maximilians - University of Munich (1) · Mayo Clinic (1) · Prof. Dr. Wolfgang Hiddemann (1) · Reid Merryman, MD (1) · The Lymphoma Academic Research Organisation (1)
United States (10) · France (3) · Germany (3) · China (2) · Czechia (2) · Italy (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Georgia (1) · Hungary (1) · Poland (1) · Russia (1)
David A Bond, MD (1) · Jonathon B Cohen, MD, MS (1) · Marcus Messmer (1) · Rachel Salit (1) · Reid Merryman, MD (1) · Ubaldo Martinez-Outschoorn, MD (1) · Usama Gergis, MD (1) · Wolfgang Hiddemann, Prof. (1) · Wolfgang Hiddemann, Prof.Dr. (1) · Yi Lin, MD, PhD (1)
PMID 30742566, PMID 39240498, PMID 40536814, PMID 40550489, PMID 41100801, PMID 42745632
2014 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), P30CA015704 (1), P30CA138292 (1), P50CA097274 (1), R01CA219960 (1)